首页> 外文期刊>The Journal of Nuclear Medicine >An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors
【24h】

An Intrapatient Comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-Octreotide for Diagnosis of Somatostatin Receptor-Expressing Tumors

机译:体内比较99mTc-EDDA / HYNIC-TOC和111In-DTPA-奥曲肽对生长抑素受体表达肿瘤的诊断

获取原文
           

摘要

The aim of this study was to compare the imaging abilities of the recently developed somatostatin analog, 99mTc-hydrazinonicotinyl-Tyr3-octreotide (99mTc-HYNIC-TOC [99mTc-TOC]), with 111In-diethylenediaminepentaacetic acid-d-Phe1-octreotide (111In-OCT [Octreoscan]) in patients undergoing routine somatostatin receptor (SSTR) scintigraphy. Methods: Forty-one patients (20 men, 21 women; age range, 29a€“75 y; mean age, 56.7 y) with either histologically proven or biologically and clinically suspected endocrine tumors were enrolled in the study. Four groups were distinguished: (a) patients being evaluated for the detection and localization of neuroendocrine tumors (n = 6), (b) tumor staging (n = 19), (c) patients being investigated to determine the SSTR status of tumor lesions (n = 11), and (d) patient follow-up studies (n = 5). Each patient received a mean activity of 150 MBq 111In-OCT and 350a€“400 MBq 99mTc-TOC. Scintigraphy with 99mTc-TOC was performed 4 h after injection and scintigraphy with 111In-OCT was performed 4 and 24 h after injection. SPECT studies of areas of interest were performed 4 h after injection for both tracers as well as at 24 h after injection for 111In-OCT. The time interval between the studies using each tracer ranged from 2 to 22 d (mean interval, 9.3 d). Results: 111In-OCT and 99mTc-TOC showed an equivalent scan result in 32 patients (78%), 9 cases showed discrepancies (22%), false-negative results with 111In-OCT were seen in 6 cases (14.6%), whereas 99mTc-TOC was false-positive in 2 cases (4.9%). 111In-OCT was true-negative in both cases. The false-positive findings of the 99mTc-TOC studies were caused by nonspecific uptake in the bowel. In 1 case, 99mTc-TOC correctly identified a metastasis in the lumbar spine but both scan results were false-positive because of an inflammatory process. In 21 patients with SSTR-expressing tumors, the semiquantitative region-of-interest analysis showed that 99mTc-TOC achieved higher tumor-to-normal tissue ratios than 111In-OCT. Conclusion: This study revealed a higher sensitivity of 99mTc-TOC as compared with 111In-OCT as an imaging agent for the localization of SSTR-expressing tumors. To avoid false-positive findings with 99mTc-OCT due to nonspecific tracer accumulation, additional scanning at 1a€“2 h after injection should be done.
机译:这项研究的目的是比较最近开发的生长抑素类似物99mTc-肼基烟碱酰基-Tyr3-奥曲肽(99mTc-HYNIC-TOC [99mTc-TOC])和111In-二亚乙基二胺五乙酸-d-Phe1-奥曲肽(接受常规生长抑素受体(SSTR)闪烁显像的患者的111In-OCT [Octreoscan]。方法:本研究纳入了41例经组织学证实或经生物学和临床怀疑为内分泌肿瘤的患者(男20例,女21例;年龄29岁至75岁;平均年龄56.7岁)。分为四组:(a)正在评估神经内分泌肿瘤的检测和定位的患者(n = 6),(b)肿瘤分期(n = 19),(c)正在研究以确定肿瘤病变的SSTR状态的患者(n = 11),以及(d)患者随访研究(n = 5)。每位患者的平均活动度为150 MBq 111In-OCT和350a×400 MBq 99mTc-TOC。注射后4 h用99mTc-TOC进行闪烁扫描,注射后4和24 h用111In-OCT进行闪烁扫描。两种示踪剂在注射后4 h以及在111 In-OCT注射后24 h进行了感兴趣区域的SPECT研究。使用每个示踪剂进行研究之间的时间间隔为2至22 d(平均间隔为9.3 d)。结果:111In-OCT和99mTc-TOC在32例患者中显示了相同的扫描结果(78%),9例显示了差异(22%),6例中发现了111In-OCT的假阴性结果(14.6%),而99例Tc-TOC假阳性2例(4.9%)。在两种情况下,111In-OCT均为真阴性。 99mTc-TOC研究的假阳性结果是由肠内非特异性摄取引起的。在1例病例中,99mTc-TOC正确地识别了腰椎中的转移,但由于炎症过程,两个扫描结果均为假阳性。在21例表达SSTR的肿瘤患者中,半定量目标区域分析显示,与111In-OCT相比,99mTc-TOC获得了更高的肿瘤与正常组织比。结论:这项研究表明,与111In-OCT相比,99mTc-TOC对SSTR表达肿瘤的定位具有更高的敏感性。为避免由于非特异性示踪剂的积累而导致99mTc-OCT出现假阳性结果,应在注射后1至2小时进行额外的扫描。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号